SEAGEN INC (SGEN)
US81181C1045 - Common Stock
Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come
A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca Plc’s $1 billion deal to acquire closely-held Amolyt Pharma illustrates, the likelihood is there’s much more to come.
3 Steal-of-a-Deal Stocks to Snap Up Right Now
Here are three steal-of-a-deal stocks that offer meaningful upside for investors looking for stocks that are on sale now.
Get Rich Quick with These 7 Growth Stocks to Buy Now
Here are seven growth stocks to buy that will let you know by their price action if the current bull market is ready to expand.
7 Dividend Stocks to Buy at a 52-Week Low
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.
Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market
Pfizer is in Wall Street's doghouse, but don't despair. At its current price, value seekers ought to relish the opportunity to buy PFE stock.
Pfizer Q4 results in focus amid gloomy outlook (NYSE:PFE)
Pfizer (PFE) is set to release its Q4 2023 results amid rising bearish bets on its earnings outlook due to headwinds against its COVID-19 franchise. Read more here.
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.
Pfizer loses Enhertu patent dispute with Daiichi (NYSE:PFE)
Pfizer's (PFE) recent buyout, Seagen (SGEN), has lost a patent dispute with Daiichi Sankyo (DSKYF) with AstraZeneca (AZN) over cancer therapy Enhertu. Read more here.
As Pfizer’s Star Power Fades, CEO Pledges Comeback on Cancer Drugs
After a miserable 2023, Pfizer Inc. Chief Executive Officer Albert Bourla says he’s rapidly taking action to fix things and pegging the company’s hopes on one of the most competitive areas of pharma for growth: cancer.
3 Stocks That Are About to Get Absolutely Crushed
These are a few different companies that are experiencing difficult times and that are expected to keep falling.
Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. (NYSE: PFE),
Pfizer closes Seagen acquisition (NYSE:PFE)
Pfizer (PFE) completes its $43B acquisition of Seagen (SGEN), boosting its oncology pipeline and projecting a $3.1B contribution from target next year. Read more here.
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen.
3 Sleepy Stocks Ready to Wake up in 2024
Strong projected earnings growth makes these three stocks strong candidates for exceptional growth in 2024.
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target.
Pfizer stock slips as 2024 guidance disappoints (NYSE:PFE)
Pfizer (PFE) stock takes a hit as the company announces lower-than-expected guidance for 2024, including the impact of its acquisition of Seagen (SGEN). Read more here.
Notable Tuesday Option Activity: SGEN, PLL, TRIP
Capri Holdings gains amid report on China review of Tapestry deal (NYSE:CPRI)
Capri Holdings (CPRI) sees a 1.6% rise as its sale to Tapestry (TPR) undergoes a simple review in China, expected to clear at $57 per share.
Nasdaq 100 Movers: LCID, SGEN
Pfizer to Close $43 Billion Seagen Acquisition After FTC Nod
Pfizer Inc. said it will close its $43 billion takeover of Seagen Inc. later this week and will donate the rights from sales of a key drug to appease US trade regulators’ concerns.
Pfizer to close Seagen buyout this week as regulatory reviews complete (NYSE:PFE)
Pfizer (PFE) receives necessary approvals to complete its acquisition of Seagen (SGEN) this week as it addresses antitrust concerns. Read more here.
3 Blue-Chip Stocks Set to Make a Comeback in 2024
These are the blue-chip stocks to buy as they represent quality companies with a steady growth outlook and promising cash flow growth.
First Week of December 15th Options Trading For Seagen (SGEN)
Seagen's breast cancer drug shows positive results in combination therapy trial
Seagen's cancer drug Tukysa, in combination with Kadcyla, meets primary endpoint in Phase 3 trial for HER2-positive metastatic breast cancer.
Seagen stock gains amid options trades, optimism for FTC approval for Pfizer deal
Seagen (SGEN) stock rises amid optimism for FTC approval of Pfizer (PFE) deal.